Up | AC
Home Page
Food and
Drug Administration
Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee, and the Pediatric Advisory Committee
December 10 & 11, 2008
BRIEFING INFORMATION
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §
552).
FDA Briefing Material (pdf)
Errata (pdf)
Bibliography (pdf)
Sponsors
Disclaimer
The statements contained in this document(s) are those of
the product's sponsor, not FDA, and FDA does not necessarily agree with the
sponsor's statements. FDA has not made a final determination about the safety
or effectiveness of the product described in this document.
Novartis
Pharmaceuticals Corporation
(pdf)
AstraZeneca (pdf)
GlaxoSmithKline (pdf)